2025
Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes
Zohora F, Nazari M, Sinusas A. Novel F-18-labeled Tracers of Sympathetic Function for Improved Risk Stratification and Clinical Outcomes. Current Cardiology Reports 2025, 27: 61. PMID: 40009333, DOI: 10.1007/s11886-025-02197-9.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter defibrillatorPositron emission tomographyImplantable cardioverter defibrillator placementMyocardial sympathetic denervationRisk stratificationSympathetic denervationIschemic heart diseaseHeart failurePrevention of sudden cardiac deathRisk stratification of patientsHeart diseaseOptimal risk stratificationLow ejection fractionStratification of patientsSympathetic nerve densityImprove risk stratificationHeart failure patientsPositron emission tomography radiotracersPredicting sudden cardiac deathPositron emission tomography tracersPrognostic benefitEjection fractionClinically practical approachNerve density
2024
Beyond HMAs: Novel Targets and Therapeutic Approaches
Getz T, Bewersdorf J, Kewan T, Stempel J, Bidikian A, Shallis R, Stahl M, Zeidan A. Beyond HMAs: Novel Targets and Therapeutic Approaches. Seminars In Hematology 2024, 61: 358-369. PMID: 39389839, DOI: 10.1053/j.seminhematol.2024.08.001.Peer-Reviewed Original ResearchAcute myeloid leukemiaDelays progression to acute myeloid leukemiaHeterogeneous group of clonal hematopoietic disordersGroup of clonal hematopoietic disordersMolecular International Prognostic Scoring SystemRandomized phase 3 clinical trialProgression to acute myeloid leukemiaInternational Prognostic Scoring SystemLower-risk MDS patientsRisk stratification of patientsPhase 3 clinical trialsCombination of azacitidineHypomethylating agent combinationsCurrent treatment landscapeFirst line therapyPrognostic Scoring SystemBiomarker-directed therapiesClonal hematopoietic disordersLack of therapeutic agentsStratification of patientsEarly phase trialsErythropoiesis stimulating agentsTreated with therapiesVariable clinical featuresStandard of careImaging Cardiac and Vascular Inflammation
Tavakoli S, Sadeghi M. Imaging Cardiac and Vascular Inflammation. 2024, 511-530. DOI: 10.1093/med/9780190095659.003.0025.Peer-Reviewed Original ResearchRisk stratification of patientsStratification of patientsPathogenesis of cardiovascular diseaseEvaluating cardiovascular pathologiesPrecision medicine toolsRisk stratificationClinical studiesEarly diagnosisInflammatory processCardiovascular diseaseMedicine toolsCardiovascular pathologyTherapeutic interventionsClinical settingImaging strategiesMolecular imagingImaging Cardiac and Vascular Inflammation
Tavakoli S, Sadeghi M. Imaging Cardiac and Vascular Inflammation. 2024, 131-133. DOI: 10.1093/med/9780197521434.003.0025.Peer-Reviewed Original ResearchRisk stratification of patientsStratification of patientsPathogenesis of cardiovascular diseaseEvaluating cardiovascular pathologiesPrecision medicine toolsRisk stratificationClinical studiesEarly diagnosisInflammatory processCardiovascular diseaseMedicine toolsCardiovascular pathologyTherapeutic interventionsClinical settingImaging strategiesMolecular imaging
2022
An Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy
Fahmy A, Csecs I, Arafati A, Assana S, Yankama T, Al-Otaibi T, Rodriguez J, Chen Y, Ngo L, Manning W, Kwong R, Nezafat R. An Explainable Machine Learning Approach Reveals Prognostic Significance of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy. JACC Cardiovascular Imaging 2022, 15: 766-779. PMID: 35033500, DOI: 10.1016/j.jcmg.2021.11.029.Peer-Reviewed Original ResearchConceptsNonischemic dilated cardiomyopathyBeth Israel Deaconess Medical CenterComposite endpointRight ventricular (RV) dysfunctionCardiovascular hospitalizationRisk prediction modelAdverse outcomesRisk markersMarker of adverse outcomeCardiac magnetic resonance markersRisk stratification of patientsRight ventricular dysfunctionRV ejection fractionMedical CenterFollow-up durationCardiac magnetic resonanceEnd-diastolic volumeStratification of patientsArea under the curveAll-cause deathHigh-risk thresholdVentricular dysfunctionEjection fractionNonischemic cardiomyopathyPrognostic significance
2020
Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists
Aminorroaya A, Vasheghani-Farahani A, Masoudkabir F, Roayaei P. Recommendations of the current guidelines for implantable cardioverter-defibrillator implantation in patients with hypertrophic cardiomyopathy: Debate still exists. Journal Of Interventional Cardiac Electrophysiology 2020, 60: 1-7. PMID: 32712900, DOI: 10.1007/s10840-020-00837-4.Peer-Reviewed Original ResearchConceptsSudden cardiac deathImplantable cardioverter-defibrillatorHypertrophic cardiomyopathySudden cardiac death risk stratificationEuropean Society of Cardiology guidelinesPrimary prevention implantable cardioverter-defibrillatorRisk stratification of patientsAmerican College of Cardiology Foundation/American Heart AssociationImplantable cardioverter-defibrillator implantationHigh-risk patientsStratification of patientsImplantation of primary prevention implantable cardioverter-defibrillatorsCardioverter-defibrillator implantationCardiology guidelinesRisk patientsVentricular arrhythmiasClinical outcomesCardiac deathCardioverter-defibrillatorHeart AssociationAmerican CollegePrimary preventionPatientsCare practitionersEuropean Society
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply